Ray David Charles, McKeown Dermot William
Department of Anaesthesia, Critical Care & Pain Medicine, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh EH16 4SA, Scotland, UK.
Crit Care. 2007;11(3):R56. doi: 10.1186/cc5916.
In seriously ill patients, etomidate gives cardiovascular stability at induction of anaesthesia, but there is concern over possible adrenal suppression. Etomidate could reduce steroid synthesis and increase the need for vasopressor and steroid therapy. The outcome could be worse than in patients given other induction agents.
We reviewed 159 septic shock patients admitted to our intensive care unit (ICU) over a 40-month period to study the association between induction agent and clinical outcome, including vasopressor, inotrope, and steroid therapy. From our records, we retrieved induction agent use; vasopressor administration at induction; vasopressor, inotrope, and steroid administration in the ICU; and hospital outcome.
Hospital mortality was 65%. The numbers of patients given an induction agent were 74, etomidate; 25, propofol; 26, thiopental; 18, other agent; and 16, no agent. Vasopressor, inotrope, or steroid administration and outcome were not related to the induction agent chosen. Corticosteroid therapy given to patients who received etomidate did not affect outcome. Vasopressor therapy was required less frequently and in smaller doses when etomidate was used to induce anaesthesia. We found no evidence that either clinical outcome or therapy was affected when etomidate was used. Etomidate caused less cardiovascular depression than other induction agents in patients with septic shock.
Etomidate use for critically ill patients should consider all of these issues and not simply the possibility of adrenal suppression, which may not be important when steroid supplements are used.
在重症患者中,依托咪酯在麻醉诱导时可维持心血管稳定,但人们担心其可能会抑制肾上腺功能。依托咪酯可能会减少类固醇合成,并增加血管升压药和类固醇治疗的需求。其结果可能比使用其他诱导药物的患者更差。
我们回顾了40个月期间入住我们重症监护病房(ICU)的159例感染性休克患者,以研究诱导药物与临床结局之间的关联,包括血管升压药、强心药和类固醇治疗。从我们的记录中,我们获取了诱导药物的使用情况;诱导时血管升压药的使用情况;ICU中血管升压药、强心药和类固醇的使用情况;以及医院结局。
医院死亡率为65%。接受诱导药物的患者人数分别为:依托咪酯74例;丙泊酚25例;硫喷妥钠26例;其他药物18例;未使用药物16例。血管升压药、强心药或类固醇的使用与结局与所选的诱导药物无关。接受依托咪酯的患者给予皮质类固醇治疗并不影响结局。当使用依托咪酯诱导麻醉时,血管升压药治疗的频率较低且剂量较小。我们没有发现证据表明使用依托咪酯会影响临床结局或治疗。在感染性休克患者中,依托咪酯引起的心血管抑制比其他诱导药物少。
对于重症患者使用依托咪酯应考虑所有这些问题,而不仅仅是肾上腺抑制的可能性,当使用类固醇补充剂时,这可能并不重要。